In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines

被引：0
|
作者：
Ioannis A. Avramis
Garyfallia Christodoulopoulos
Atsushi Suzuki
Walter E. Laug
Ignacio Gonzalez-Gomez
George McNamara
Edward A. Sausville
Vassilios I. Avramis
机构：
[1] Division of Hematology/Oncology,
[2] Department of Pediatrics,undefined
[3] Childrens Hospital Los Angeles,undefined
[4] USC Keck School of Medicine,undefined
[5] 4650 Sunset Blvd,undefined
[6] Los Angeles,undefined
[7] CA 90027,undefined
[8] USA,undefined
[9] Department of Pathology,undefined
[10] Childrens Hospital Los Angeles,undefined
[11] USC Keck School of Medicine,undefined
[12] Los Angeles,undefined
[13] CA,undefined
[14] USA,undefined
[15] National Cancer Institute,undefined
[16] Rockville,undefined
[17] MD,undefined
[18] USA,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2002年 / 50卷
关键词：
Tyrosine kinase Leukemia Brain tumors Apoptosis VEGF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Abstract
引用
收藏
页码：479 / 489
页数：10
相关论文
共 50 条
  • [1] In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines
    Avramis, IA
    Christodoulopoulos, G
    Suzuki, A
    Lang, WE
    Gonzalez-Gomez, I
    McNamara, G
    Sausville, EA
    Avramis, VI
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (06) : 479 - 489
  • [2] Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines
    Avramis, IA
    Laug, WE
    Sausville, EA
    Avramis, VI
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (04) : 307 - 318
  • [3] Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines
    Ioannis A. Avramis
    Walter E. Laug
    Edward A. Sausville
    Vassilios I. Avramis
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 307 - 318
  • [4] In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation
    E. Ranza
    G. Mazzini
    A. Facoetti
    R. Nano
    Journal of Neuro-Oncology, 2010, 96 : 349 - 357
  • [5] In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation
    Ranza, E.
    Mazzini, G.
    Facoetti, A.
    Nano, R.
    JOURNAL OF NEURO-ONCOLOGY, 2010, 96 (03) : 349 - 357
  • [6] Synergistic effects of protein tyrosine kinase inhibitor genistein with camptothecins against three cell lines in vitro
    Papazisis, KT
    Kalemi, TG
    Zambouli, D
    Geromichalos, GD
    Lambropoulos, AF
    Kotsis, A
    Boutis, LL
    Kortsaris, AH
    CANCER LETTERS, 2006, 233 (02) : 255 - 264
  • [7] Modulation of signaling pathways by adaphostin (NSC-680410), an antileukemic tyrosine kinase inhibitor: the past, the present and recommendations for the future
    Avramis, VL
    DRUGS OF THE FUTURE, 2003, 28 (11) : 1087 - 1102
  • [8] Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo
    Xishan Xiong
    Lili Fu
    Li Wang
    Houan Cai
    Lin Li
    Hualiang Jiang
    Wenhu Duan
    Changlin Mei
    Investigational New Drugs, 2009, 27
  • [9] Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo
    Xiong, Xishan
    Fu, Lili
    Wang, Li
    Cai, Houan
    Li, Lin
    Jiang, Hualiang
    Duan, Wenhu
    Mei, Changlin
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (01) : 1 - 11
  • [10] Effect of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro
    Svingen, PA
    Tefferi, A
    Kottke, TJ
    Kaur, G
    Narayanan, VL
    Sausville, EA
    Kaufmann, SH
    CLINICAL CANCER RESEARCH, 2000, 6 (01) : 237 - 249
12345